Indo-MIM Limited — the world's largest Metal Injection Molding company — is going public with a ₹3,811 crore IPO opening on July 23, 2026. With a grey market premium of +₹188 (+39%) already pricing in strong listing gains, this Bengaluru-based global manufacturer is one of the most anticipated mainboard IPOs of the month. Here is everything you need to know before you apply.
Indo-MIM IPO — Key Details at a Glance
- IPO Open Date: July 23, 2026
- IPO Close Date: July 27, 2026
- Allotment Date: July 28, 2026
- Listing Date: July 30, 2026 (NSE & BSE)
- Price Band: ₹461 – ₹485 per share
- Lot Size: 30 shares | Minimum Investment: ₹14,550 (retail)
- Issue Size: ₹3,811.21 crore (Fresh Issue ₹499.10 Cr + OFS ₹3,312.11 Cr)
- Investor Quota: QIB 50% | NII 15% | Retail 35%
- GMP Today: +₹188 (+39%) — Estimated Listing ~₹673
- Face Value: ₹1 per share
About Indo-MIM — The World's Largest MIM Company
Founded in 1996 and headquartered in Bengaluru, India, Indo-MIM (Indo Metal Injection Moulding) is a fully integrated, global manufacturer of high-precision engineered components. The company is the world's leading producer using Metal Injection Molding (MIM) — a manufacturing process that combines the design flexibility of plastic injection molding with the material properties of metals, enabling highly complex, miniaturized metal parts at scale.
Indo-MIM serves over 1,100 customers across 50+ countries, supplying critical components to industries including Automotive, Aerospace & Defence, Medical Devices, Consumer Electronics, and Industrial Engineering. Its global footprint includes manufacturing facilities in India and subsidiaries in the USA (Triax Industries) and the UK (CMG Technologies), making it a truly multinational precision manufacturer.
With over 4,000 skilled employees, the company has built capabilities across the full manufacturing value chain — from design and tooling to materials, finishing, and assembly. Beyond MIM, Indo-MIM also operates advanced manufacturing technologies including Binder Jet 3D Printing, Laser Powder Bed Fusion (LPBF), and Ceramic Injection Molding, positioning itself at the frontier of additive manufacturing.
What is Metal Injection Molding (MIM)?
Metal Injection Molding is a manufacturing process where fine metal powders are mixed with a binder material to create a feedstock that is injected into a mold — just like plastic injection molding. The resulting 'green' part is then processed through debinding and sintering to produce a dense, high-precision metal component with excellent mechanical properties.
MIM is ideal for producing complex, small, high-volume metal parts that would be too expensive or impossible to machine traditionally. Applications range from firearm components, surgical instruments, and automobile fuel injectors to drone parts, implantable medical devices, and consumer electronics. The global MIM market is growing at a CAGR of 8–10%, driven by miniaturization trends in automotive and medical industries.
Indo-MIM Financial Performance
- Revenue FY2026: ₹4,320.70 crore (vs ₹3,373.97 crore in FY2025 — +28% YoY)
- Net Profit (PAT) FY2026: ₹533.54 crore (vs ₹423.73 crore in FY2025 — +26% YoY)
- Consistent double-digit revenue and profit growth over multiple years
- Export-heavy model — primary markets are USA and Europe
- Fresh issue proceeds (₹499.10 Cr) to fund capacity expansion and general corporate purposes
The financial story is compelling: 28% revenue growth and 26% PAT growth in FY2026 demonstrate that Indo-MIM is firing on all cylinders. As global OEMs seek reliable, high-precision component suppliers outside China, Indo-MIM is well placed to capture this 'China+1' opportunity in precision manufacturing.
GMP Analysis — What Does +39% Signal?
As of July 22, 2026, Indo-MIM IPO GMP stands at +₹188 per share, implying a +39% premium over the upper price band of ₹485. Based on this, the estimated listing price is approximately ₹673. GMP has been tracked at ₹181–₹195 from multiple sources, indicating a stable and strong grey market consensus — not just speculative noise.
A +39% GMP on a ₹3,811 crore mainboard IPO is a significant signal. It reflects institutional-level confidence, strong retail enthusiasm, and expectations of robust subscription across all investor categories. However, GMP is an informal and unregulated indicator — actual listing prices can vary. IPOLyst tracks live GMP daily across all active IPOs at ipolyst.com.
Key Strengths
- Global market leader: World's largest Metal Injection Molding company by capacity
- Diversified end markets: Auto, Aerospace, Defence, Medical, Consumer — no single sector dominance
- 1,100+ global customers across 50+ countries — sticky, long-term relationships
- China+1 beneficiary: Global OEMs actively diversifying supply chains away from China
- Advanced technology: MIM + Additive Manufacturing (3D Printing) capabilities
- Strong financials: 28% revenue growth, 26% PAT growth in FY2026
- Global acquisitions: CMG Technologies (UK) + Triax Industries (USA) expand capabilities
- India-based cost advantage: Lower manufacturing costs vs Western competitors
Key Risks
- OFS-heavy IPO: ₹3,312 crore out of ₹3,811 crore is Offer for Sale — promoters selling, not the company raising fresh capital
- Export dependency: ~70–80% revenues from USA and Europe — vulnerable to forex movements and recession risk
- Raw material costs: Metal powder prices can be volatile and squeeze margins
- Concentrated customer risk: Top customers likely account for significant revenue share
- Global competition: Faces competition from Dynacast, Smith Metal Products, Parmatech globally
- Premium valuation: At ₹485, the IPO is not cheap — priced for near-perfection
Valuation — Is the Price Band Reasonable?
At the upper price band of ₹485, Indo-MIM is valued at approximately ₹38,000–40,000 crore (market cap). Given FY2026 PAT of ₹533.54 crore, this implies a Price-to-Earnings (P/E) ratio of roughly 72–75x. This is a premium valuation compared to most traditional manufacturing companies, but justified given the niche global leadership position, strong growth trajectory, and the scarcity premium for a pure-play MIM manufacturer in public markets. The GMP of +39% suggests the market agrees the issue is priced attractively enough to deliver listing gains.
Our Verdict — Apply or Avoid?
Indo-MIM IPO gets our APPLY rating for both listing gains and long-term holding. Here is why:
- Strong fundamentals: 28%/26% revenue/profit growth is not common at this scale
- Global niche leadership: No comparable listed pure-play MIM peer globally
- GMP of +39% with stable consensus signals strong institutional demand
- China+1 tailwind: This structural shift in global supply chains is real and multi-year
- Mainboard credibility: Retail and HNI allocation gives broad access
Caution: The OFS-heavy structure means promoters are monetizing at peak valuations. Apply with realistic expectations — listing gains of 25–40% are plausible, but significant allotment in retail is unlikely given the expected oversubscription.
Strategy: Apply with 2–3 lots for maximum retail allotment chances. If allotted, consider holding for 3–6 months to benefit from the China+1 order flow tailwind.
Disclaimer
Disclaimer: This review is for informational purposes only and does not constitute financial advice. IPOLyst is not a SEBI-registered investment advisor. GMP figures are informal and sourced from grey market participants — they do not guarantee listing prices. Please conduct your own research and consult a qualified financial advisor before making any investment decisions.